Christal M.M. Mickle is the interim CEO of Zevra Therapeutics, Inc., a company she co-founded in 2006 focused on pharmaceutical development. She holds a Master’s degree in Medicinal Chemistry from the University of Virginia, along with dual Bachelor’s degrees in...

Christal M.M. Mickle is the interim CEO of Zevra Therapeutics, Inc., a company she co-founded in 2006 focused on pharmaceutical development. She holds a Master’s degree in Medicinal Chemistry from the University of Virginia, along with dual Bachelor’s degrees in Chemistry and Biochemistry from Virginia Tech. With over 20 years in the pharmaceutical field, Christal has played a crucial role in guiding the development of new drug applications, notably contributing to the approval of three major drugs. Before stepping into the CEO role temporarily in June 2023, she served as the Chief Development Officer and has held various other strategic positions at Zevra. It’s interesting to note that during 2023, her compensation totaled about 1.7 million USD, which reflects her salary, bonuses, and a significant amount from stock options that vested. Christal's deep background also includes start-up experience with New River Pharmaceuticals, where she began her career as a Research Associate. Her focus on innovation and efficient development can significantly influence Zevra's growth trajectory in the highly competitive pharmaceutical landscape.

Quick Links

1. Rivals

2. Holdings

3. Insider Trading

4. Compensation History

5. Other Zevra Therapeutics, Inc. CEOs

Z

Christal M.M. Mickle

Founder and Ex-CEO of Zevra Therapeutics, Inc.

Education

M.A. degree in Medicinal Chemistry from the University of Virginia; B.A. and B.S. degrees in Chemistry and Biochemistry from Virginia Polytechnic Institute and State University

Sector of Economy

Healthcare

Born

January 1, 1979 - 46 years ago

CEO of Zevra Therapeutics, Inc. for

0 years 4 months (Jun 2023 - Oct 2023)

Previous Experience

Senior Vice President, Operations and Product Development at Zevra Therapeutics, Inc.

Rivals

Competitors/colleagues of Christal M.M. Mickle

Holdings

See how much did Christal M.M. Mickle make over time.

Christal Mickle has shown considerable investment in Zevra Therapeutics, holding a significant amount of its common stock. As of recent reports, she beneficially owns over 1.8 million shares directly. This represents a major part of her net worth, with fluctuations...

Christal Mickle has shown considerable investment in Zevra Therapeutics, holding a significant amount of its common stock. As of recent reports, she beneficially owns over 1.8 million shares directly. This represents a major part of her net worth, with fluctuations indicating a strong tie to the company. In previous years, she had stocks that represented a much larger share of her wealth, but the current landscape shows her commitment to Zevra's future. The company's stock performance has varied, influencing her holdings' value. Despite the ups and downs, her steadfast position showcases her belief in the company's vision and potential.

Insider Trading

See recent insider trades of Christal M.M. Mickle.

No insider trades found for this CEO.

Compensation History

See how much did Christal M.M. Mickle make over time.

In 2023, Christal Mickle's total compensation reached approximately 1.7 million USD. This included a base salary of 512,000 USD, a bonus of 173,264 USD based on performance metrics, and substantial amounts from stock options that vested during the year. Her compensation plan is designed to align her incentives with those of the shareholders, as it includes both salary and performance-based bonuses. The stock grants reflect a commitment to long-term growth, creating a direct link between her performance and the company's success. Overall, her compensation package emphasizes the importance of reaching key corporate objectives and delivering results.

Year

2023

Total Compensation

$2.05M

Salary

$512.00K

Board Justification

The compensation philosophy aims to attract, retain, and motivate talented executives, aligning their interests with those of stockholders through performance-based incentives.

Bonus

$173.26K

Board Justification

Annual performance-based bonus opportunity based on achievement of corporate performance objectives for the year 2023.

Other

$13.60K

Board Justification

Includes 401(k) employer matching contributions and premiums paid for life insurance policies.

Restricted Stock

$1.35M(300K Stock options)

Board Justification

Stock options granted in 2023 that vested during the year.

Performance Metrics

Performance metrics for the bonus included the achievement of specified development, regulatory, and financial milestones.

Other Zevra Therapeutics, Inc. CEOs

Here are other CEOs of Zevra Therapeutics, Inc.

Richard W. Pascoe

Ex-CEO of Zevra Therapeutics, Inc.

January 2023 - June 2023

Neil F. McFarlane

CEO of Zevra Therapeutics, Inc.

October 2023 - Present